October 22, 2009
Presentation of Phase 2 Data on ATX-101, a First-in- Class, Novel, Injectable Drug For The Reduction of Localized Fat and New Data on Pharmacokinetics, Histology and MOA.
The American Society of Plastic Surgeons (ASPS) Plastic Surgery 2009 Conference, Seattle, WA
In a rapidly growing market of minimally-invasive, non-surgical facial rejuvenation, the reduction of facial fat deposits to restore and reshape the jawline remains one of the largest unmet patient needs. Currently there are no FDA approved drugs to reduce excess localized fat.
KYTHERA is developing ATX-101 to address this need. ATX-101 is a first-in-class injectable drug for the reduction of localized fat. The initial application of ATX-101 is for the reduction of submental (under the chin) fat.
ATX-101 is a first-in-class injectable drug being studied for the reduction of small volumes of fat. It is based on an endogenous compound with unique features including selectivity for adipocytes and rapid clearance. ATX-101 clinical research is focused on reducing localized fat deposits, including submental fat. KYTHERA has completed two randomized, double-blind, placebo-controlled, Phase 2 studies for the reduction of submental fat and two Phase 1 studies: pharmacokinetics and histology.